https://pharminent.com/eli-lilly-smashes-q2-estimates-raises-2026-guidance-to-85-87b-on-glp-1-surge/ 2026-08-05T21:40:07Z Pharminent en Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 Surge 2026-08-05T20:08:15Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-5-2026/ 2026-08-05T19:26:41Z Pharminent en Strategic News Watch • August 5, 2026 2026-08-05T16:09:19Z Blog https://pharminent.com/gilead-looks-to-upcoming-inflammation-cancer-catalysts-as-pressure-to-diversify-mounts/ 2026-08-05T21:40:53Z Pharminent en Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts 2026-08-05T13:34:14Z Blog https://pharminent.com/asymbio-to-secure-184m-to-support-growth-in-biologics-manufacturing/ 2026-08-05T21:41:47Z Pharminent en AsymBio to secure $184m to support growth in biologics manufacturing 2026-08-05T09:22:12Z Blog https://pharminent.com/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-in-quarterly-pipeline-clearout/ 2026-08-04T19:31:47Z Pharminent en Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout 2026-08-04T19:30:57Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-4-2026/ 2026-08-04T18:47:07Z Pharminent en Strategic News Watch • August 4, 2026 2026-08-04T18:45:25Z Blog